U.S., May 8 -- ClinicalTrials.gov registry received information related to the study (NCT07572864) titled 'Neoadjuvant ICI and Mitochondrial Vaccine for Resectable HNSCC' on April 24.
Brief Summary: Head and neck squamous cell carcinoma (HNSCC) presents a significant clinical challenge, as over 60% of patients are diagnosed at a locally advanced stage with a high risk of recurrence. Although the landmark KEYNOTE-689 trial established neoadjuvant immune checkpoint inhibitor (ICI) therapy as a new standard of care, the pathological complete response (pCR) rate remains unsatisfactory at only 3.0%, highlighting an urgent need for optimized combination strategies. This prospective, single-arm, single-center clinical study aims to evaluate the s...